- Home
- PLG vs OABI Comparison
PLG vs OABI Comparison
Compare PLG & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLG | OABI |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 239.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PLG | OABI |
|---|---|---|
| Price | $2.46 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | ★ 2.0M | 518.6K |
| Earning Date | 01-13-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 3.36 |
| 52 Week Low | $0.99 | $1.22 |
| 52 Week High | $3.36 | $4.17 |
Technical Indicators
Market Signals| Indicator | PLG | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 59.35 | 65.31 |
| Support Level | $2.32 | $1.69 |
| Resistance Level | $2.49 | $1.64 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 88.31 | 86.06 |
Price Performance
Historical ComparisonAbout PLG Platinum Group Metals Ltd. (Canada)
Platinum Group Metals Ltd is the operator of the Waterberg Project, a bulk underground PGM deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, the Japan Oil, Gas and Metals National Corporation (JOGMEC) and Hanwa Co. Ltd. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium, and gold. Geographically, it operates in Canada and South Africa.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.